Since the publication of the Osteoporosis Canada guide-lines in 2002, there has been a
paradigm shift in the prevention and treatment of osteoporosis and fractures. 1, 2 The focus now …

Hypophosphatemia is a genetically heterogeneous disease. Here, we mapped an autosomal
recessive form (designated ARHP) to chromosome 4q21 and identified homozygous …

Osteoporosis is the most common cause of fragility fractures. Bone remodelling is essential
for repairing damaged areas within bone to preserve bone strength and for assisting in …

Objective To outline the efficacy and risks of bisphosphonate therapy for the management of
osteoporosis and describe which patients might be eligible for bisphosphonate “drug …

OBJECTIVE: To summarize the current knowledge regarding the various determinants of
bone strength. METHODS: Relevant English-language articles acquired from Medline from …

We previously reported that urokinase (uPA) is produced by the human prostate cancer cell
line, PC-3, and could function as a growth factor for cells of the osteoblast phenotype. To …

OBJECTIVES: Proton pump inhibitor (PPI) use has been identified as a risk factor for hip and
vertebral fractures. Evidence supporting a relationship between PPI use and osteoporosis …

The warm-up programme “FIFA 11+” has been shown to reduce football injuries in different
populations, but so far veteran players have not been investigated. Due to differences in age, …

OBJECTIVE We aimed to explore whether frailty was associated with fracture risk and whether
frailty could modify the propensity of type 2 diabetes toward increased risk of fractures. …

OBJECTIVE We aimed to assess whether individuals with type 2 diabetes (T2D) have increased
risk of vertebral fractures (VFs) and to estimate nonvertebral fracture and mortality risk …